- Home
- AARD vs TZOO Comparison
AARD vs TZOO Comparison
Compare AARD & TZOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- TZOO
- Stock Information
- Founded
- AARD 2017
- TZOO 1998
- Country
- AARD United States
- TZOO United States
- Employees
- AARD N/A
- TZOO N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- TZOO Advertising
- Sector
- AARD Health Care
- TZOO Consumer Discretionary
- Exchange
- AARD Nasdaq
- TZOO Nasdaq
- Market Cap
- AARD 154.9M
- TZOO 166.1M
- IPO Year
- AARD 2025
- TZOO 2002
- Fundamental
- Price
- AARD $10.14
- TZOO $14.51
- Analyst Decision
- AARD Strong Buy
- TZOO Strong Buy
- Analyst Count
- AARD 4
- TZOO 4
- Target Price
- AARD $31.50
- TZOO $23.00
- AVG Volume (30 Days)
- AARD 69.4K
- TZOO 152.8K
- Earning Date
- AARD 01-01-0001
- TZOO 04-29-2025
- Dividend Yield
- AARD N/A
- TZOO N/A
- EPS Growth
- AARD N/A
- TZOO 10.54
- EPS
- AARD N/A
- TZOO 1.00
- Revenue
- AARD N/A
- TZOO $85,057,000.00
- Revenue This Year
- AARD N/A
- TZOO $16.43
- Revenue Next Year
- AARD N/A
- TZOO $25.78
- P/E Ratio
- AARD N/A
- TZOO $14.67
- Revenue Growth
- AARD N/A
- TZOO 0.23
- 52 Week Low
- AARD $4.88
- TZOO $7.12
- 52 Week High
- AARD $19.58
- TZOO $24.85
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- TZOO 54.53
- Support Level
- AARD N/A
- TZOO $13.22
- Resistance Level
- AARD N/A
- TZOO $15.48
- Average True Range (ATR)
- AARD 0.00
- TZOO 1.28
- MACD
- AARD 0.00
- TZOO 0.15
- Stochastic Oscillator
- AARD 0.00
- TZOO 52.55
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About TZOO Travelzoo
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; and Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties. Most of the company's revenue is derived from North America.